AI
By
Is AbCellera Biologics Building a Durable AI Antibody Discovery Engine as Pharma Partnerships Signal Multi-Billion-Dollar Potential?
Executive Summary AbCellera Biologics has established itself as a global leader in AI-driven antibody discovery, combining advanced computational…
Is Recursion Pharmaceuticals Setting the Standard for AI-Powered Drug Discovery with Strategic Deals and a $20B+ Partnership Pipeline?
Executive Summary Recursion Pharmaceuticals has emerged as a leading clinical-stage TechBio company applying artificial intelligence, automation, and large-scale…
Can ReviR’s AI-Powered RNA Modulation Platform Convert $50M+ in Funding into Scalable Genetic Medicines?
Executive Summary ReviR Therapeutics continues to establish itself as a leader in RNA-targeting small molecule drug discovery, advancing…
Can Ainnocence’s Causal AI Platform Redefine Drug Discovery Value as Pharma Expands AI Partnerships?
Strategic Overview Ainnocence is carving out a differentiated role in AI-driven drug discovery by emphasizing causal, mechanism-oriented artificial…
Drugmakers Use AI to Speed Trials and Regulatory Filings
Pharmaceutical companies are increasingly using artificial intelligence to streamline clinical trials and regulatory filings. While AI has not…
AI Is Reshaping Pharma’s Economics—But Discovery Isn’t the Immediate Win
Executive Summary Artificial intelligence has moved from experimental promise to operational backbone across global biopharma. Industry leaders including…
